Rebalancing Neuronal Chloride Signaling to Reverse Early Cognitive Decline: Repurposing Bumetanide for Mild Dementia
Bibliographic record
Abstract
Dementia is traditionally viewed as progressive and irreversible, yet new research suggests that cognitive decline may be partly reversible when neuronal signaling balance is restored. Bumetanide, a loop diuretic widely used for edema, has recently gained attention for its ability to block the NKCC1 chloride co-transporter in neurons, thereby restoring inhibitory GABAergic signaling. This study evaluated the potential therapeutic effects of bumetanide in individuals with mild cognitive impairment (MCI) and early-stage dementia. A total of 60 participants aged 58–82 years were enrolled in a 24-week randomized controlled pilot trial. Participants received either bumetanide (0.5–1 mg/day) plus standard care, or standard care alone. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), ADAS-Cog, and memory subtests. Neurodegeneration biomarkers (plasma p-tau181, neurofilament light chain) and hippocampal volume on MRI were evaluated at baseline and week 24. The bumetanide group demonstrated a statistically significant improvement in MoCA (+2.1 ± 0.8; p < 0.05) and reduced ADAS-Cog scores compared with controls. Biomarker analysis suggested mild reductions in p-tau181 and neurofilament light levels, alongside stabilization of hippocampal volume loss. No severe adverse events were reported. These findings support bumetanide as a promising repurposed therapy that targets neuronal chloride imbalance and may contribute to partial reversal of cognitive decline in early dementia. Larger, multi-center trials are warranted.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".